Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act. H.R.1157 - ACCESS Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails Issues related to CMS fixed-dose combination drugs for Initial Price Applicability Year 2029 (CMS-4215-P)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| EMD SERONO, INC. |
| 12 |
| 2023–2025 |
| AMERICAN OCCUPATIONAL THERAPY ASSOCIATION | 11 | 2024–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 11 | 2024–2026 |
| VIVEX BIOLOGICS | 10 | 2024–2026 |
| ACESSO BIOLOGICS | 8 | 2025–2026 |
| BIOWOUND SOLUTIONS | 8 | 2025–2026 |
| DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. | 6 | 2023–2024 |
| PTC THERAPEUTICS, INC. | 6 | 2022–2023 |
| AMGEN | 5 | 2024–2025 |
| AVADEL PHARMACEUTICALS | 5 | 2023–2024 |
| ROCHE DIAGNOSTICS | 5 | 2024–2026 |
| BRISTOL-MYERS SQUIBB | 4 | 2025–2026 |
| DENDREON PHARMACEUTICALS, LLC | 4 | 2023–2024 |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 4 | 2025–2026 |
| VENTURE MEDICAL | 4 | 2026 |
| WEX HEALTH | 4 | 2025–2026 |
| ALKERMES, INC. | 3 | 2023 |
| ROYAL BIOLOGICS | 3 | 2025–2026 |
| VIALASE INC. | 3 | 2026 |
| GENENTECH | 1 | 2026 |
| HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) | 1 | 2023 |
To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Medicare Home Health Accessibility Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Medicare Home Health Accessibility Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Medicare Home Health Accessibility Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Seniors’ Access to Critical Medications Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Seniors’ Access to Critical Medications Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues Related to the Provider Reimbursement Stability Act of 2026 (H.R.8163).
Seniors’ Access to Critical Medications Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues related to the Provider Reimbursement Stability Act of 2026 (H.R.8163). Issues related to the Patients First Act of 2026 (H.R.9693)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare payment and beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091) Promoting Fairness for Medicare Providers Act of 2026 (H.R. 7863)
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Occupational Therapy Mental Health Parity Act.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Occupational Therapy Mental Health Parity Act.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Occupational Therapy Mental Health Parity Act.
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
CONNECT for Health Act of 2025
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
CONNECT for Health Act of 2025
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
CONNECT for Health Act of 2025
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Protecting Patient Access to Cancer and Complex Therapies Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues Related to the Provider Reimbursement Stability Act of 2026 (H.R.8163).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Protecting Patient Access to Cancer and Complex Therapies Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues related to the Provider Reimbursement Stability Act of 2026 (H.R.8163). Issues related to the Patients First Act of 2026 (H.R.9693)
No Surprises Act Enforcement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420). Issues relating to the Federal Independent Dispute Resolution Operations proposed rule
No Surprises Act Enforcement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420). Issues relating to the Federal Independent Dispute Resolution Operations proposed rule
No Surprises Act Enforcement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420). Issues relating to the Federal Independent Dispute Resolution Operations proposed rule
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Ensuring Patient Access to Critical Breakthrough Products Act
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ROCHE DIAGNOSTICS · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Ensuring Patient Access to Critical Breakthrough Products Act
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act. H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act. H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act
Patients Deserve Price Tags Act
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. S.2355/H.R.5582 - Patients Deserve Price Tags Act. Issues related to Lower Costs, More Transparency Act of 2026 (H.R.9393)
Patients Deserve Price Tags Act
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. Issues related to Patients Deserve Price Tags Act (S.2355/H.R.5582). Issues related to Lower Costs, More Transparency Act of 2026 (H.R.9393). Issues related to Health Care Price Certainty for All Americans Act (H.R.9645).
Skin Substitute Access and Payment Reform Act
Client: VIVEX BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Skin Substitute Access and Payment Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Skin Substitute Access and Payment Reform Act
Client: VIVEX BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Skin Substitute Access and Payment Reform Act
Client: BIOWOUND SOLUTIONS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Skin Substitute Access and Payment Reform Act
Client: ROYAL BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Skin Substitute Access and Payment Reform Act
Client: ACESSO BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Skin Substitute Access and Payment Reform Act
Client: BIOWOUND SOLUTIONS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Skin Substitute Access and Payment Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Skin Substitute Access and Payment Reform Act
Client: ACESSO BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Skin Substitute Access and Payment Reform Act
Client: ACESSO BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Skin Substitute Access and Payment Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Skin Substitute Access and Payment Reform Act
Client: BIOWOUND SOLUTIONS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Skin Substitute Access and Payment Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ROYAL BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: BIOWOUND SOLUTIONS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: VIVEX BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: BIOWOUND SOLUTIONS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ACESSO BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ACESSO BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: VIVEX BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: ACESSO BIOLOGICS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: BIOWOUND SOLUTIONS · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Client: VENTURE MEDICAL · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Promoting Fairness for Medicare Providers Act of 2026
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare payment and beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091) Promoting Fairness for Medicare Providers Act of 2026 (H.R. 7863)
Outpatient Surgery Access Act of 2026
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare payment and beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091) Promoting Fairness for Medicare Providers Act of 2026 (H.R. 7863)
Outpatient Surgery Access Act of 2026
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091)
Outpatient Surgery Access Act of 2026
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091)
Provider Reimbursement Stability Act of 2026
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues Related to the Provider Reimbursement Stability Act of 2026 (H.R.8163).
Provider Reimbursement Stability Act of 2026
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues related to the Provider Reimbursement Stability Act of 2026 (H.R.8163). Issues related to the Patients First Act of 2026 (H.R.9693)
Issues related to Artificial Intelligences approval in Medical Devices. Issues related to The SECURE Data Act (H.R. 8413).
Issues related to Artificial Intelligences approval in Medical Devices. Issues related to The SECURE Data Act (H.R. 8413).
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues Related to the Provider Reimbursement Stability Act of 2026 (H.R.8163).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Medicare Patient Access and Practice Stabilization Act of 2025
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues related to the Provider Reimbursement Stability Act of 2026 (H.R.8163). Issues related to the Patients First Act of 2026 (H.R.9693)
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act. H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act H.R.1157 - ACCESS Act
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act
Lower Costs, More Transparency Act of 2026
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. Issues related to Patients Deserve Price Tags Act (S.2355/H.R.5582). Issues related to Lower Costs, More Transparency Act of 2026 (H.R.9393). Issues related to Health Care Price Certainty for All Americans Act (H.R.9645).
Lower Costs, More Transparency Act of 2026
Client: AMBULATORY SURGERY CENTER ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. S.2355/H.R.5582 - Patients Deserve Price Tags Act. Issues related to Lower Costs, More Transparency Act of 2026 (H.R.9393)
Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Tax Exempt Hospital Transparency Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Tax Exempt Hospital Transparency Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Tax Exempt Hospital Transparency Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to the SECURE 340B Act (H.R.9599).
ZIMMER BIOMET via THE MCMANUS GROUP
2026 · third_quarter · Q3
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Issues related to Artificial Intelligences approval in Medical Devices. Issues related to The SECURE Data Act (H.R. 8413).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2026 · third_quarter · Q3
Education on FDA regulation of Human Cellular Tissue Products (HCTPs).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIALASE INC. via THE MCMANUS GROUP
2026 · third_quarter · Q3
Patient access and reimbursement of ophthalmic medical devices. Issues related to patient access to glaucoma treatment in 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P).
Education on ophthalmic medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTURE MEDICAL via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2026 · third_quarter · Q3
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2026 · third_quarter · Q3
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420). Issues relating to the Federal Independent Dispute Resolution Operations proposed rule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Issues related to global trade and tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues related to the Provider Reimbursement Stability Act of 2026 (H.R.8163). Issues related to the Patients First Act of 2026 (H.R.9693)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2026 · third_quarter · Q3
Advocating for access to and reimbursement for biosimilars. Issues related to vertical integration and white bagging. Issues related to patient access to products for asthma and allergies.
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2026 · third_quarter · Q3
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to the SECURE 340B Act (H.R.9599).
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Policies related to the Most Favored Nation Drug Pricing Model.
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. Issues related to Patients Deserve Price Tags Act (S.2355/H.R.5582). Issues related to Lower Costs, More Transparency Act of 2026 (H.R.9393). Issues related to Health Care Price Certainty for All Americans Act (H.R.9645).
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare payment and beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091) Promoting Fairness for Medicare Providers Act of 2026 (H.R. 7863)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2026 · third_quarter · Q3
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to Artificial Intelligences approval in Medical Devices. Issues related to The SECURE Data Act (H.R. 8413).
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to tax-advantaged savings accounts for Medicare beneficiaries, including the creation and regulation of Medicare Flex Fund Accounts to cover qualified medical expenses
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act, S.2875 - CHOICE Act H.R.1157 - ACCESS Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Education on FDA regulation of Human Cellular Tissue Products (HCTPs).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIALASE INC. via THE MCMANUS GROUP
2026 · second_quarter · Q2
Education on ophthalmic medical devices.
Patient access and reimbursement of ophthalmic medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTURE MEDICAL via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2026 · second_quarter · Q2
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Issues related to global trade and tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2026 · second_quarter · Q2
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420). Issues relating to the Federal Independent Dispute Resolution Operations proposed rule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to global trade and tariffs.
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues Related to the Provider Reimbursement Stability Act of 2026 (H.R.8163).
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2026 · second_quarter · Q2
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Advocating for access to and reimbursement for biosimilars. Issues related to vertical integration and white bagging. Issues related to patient access to products for asthma and allergies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2026 · second_quarter · Q2
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB via THE MCMANUS GROUP
2026 · second_quarter · Q2
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2026 · second_quarter · Q2
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091)
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. S.2355/H.R.5582 - Patients Deserve Price Tags Act. Issues related to Lower Costs, More Transparency Act of 2026 (H.R.9393)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2026 · second_quarter · Q2
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTURE MEDICAL via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIALASE INC. via THE MCMANUS GROUP
2026 · first_quarter · Q1
Education on ophthalmic medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2026 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Education on FDA regulation of Human Cellular Tissue Products (HCTPs).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to tax-advantaged savings accounts for Medicare beneficiaries, including the creation and regulation of Medicare Flex Fund Accounts to cover qualified medical expenses
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act. H.R.1157 - ACCESS Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2026 · first_quarter · Q1
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420). Issues relating to the Federal Independent Dispute Resolution Operations proposed rule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to global trade and tariffs.
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2026 · first_quarter · Q1
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to global trade and tariffs.
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2026 · first_quarter · Q1
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM Price Transparency and Accountability Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2026 · first_quarter · Q1
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Advocating for access to and reimbursement for biosimilars. Issues related to vertical integration and white bagging.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2026 · first_quarter · Q1
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776) Outpatient Surgery Access Act of 2026 (H.R. 8091)
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. S.2355 - Patients Deserve Price Tags Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2026 · first_quarter · Q1
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261) H.R. 4037/S. 2847- Occupational Therapy Mental Health Parity Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROYAL BIOLOGICS via THE MCMANUS GROUP
2026 · first_quarter · 1T
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB via THE MCMANUS GROUP
2026 · first_quarter · Q1
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTURE MEDICAL via THE MCMANUS GROUP
2026 · first_quarter · RR
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
EMD SERONO, INC. via THE MCMANUS GROUP
2025 · fourth_quarter · 4T
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments, including the Infertility Treatment Affordability Act (H.R. 4639).
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ROYAL BIOLOGICS via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Education on Human Cellular Tissue Products (HCTPs).
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. CONNECT for Health Act of 2025 (H.R. 4206/S. 1261)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to site neutrality. Issues related to provider and insurer payment transparency. S.1629 - Same Care, Lower Cost Act. S.2355 - Patients Deserve Price Tags Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Advocating for access to and reimbursement for biosimilars.
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to virtual supervision of infusion drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to making Health Savings Accounts and Health Reimbursement Arrangements more accessible and ubiquitous, including H.R. 548- HSA Modernization Act, H.R.919 - Chronic Disease Flexible Coverage Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act, H.R. 5463 - Choice Arrangement Act. H.R.1157 - ACCESS Act
Issues related to tax-advantaged savings accounts for Medicare beneficiaries, including the creation and regulation of Medicare Flex Fund Accounts to cover qualified medical expenses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM Price Transparency and Accountability Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GRAIL, INC. via THE MCMANUS GROUP
2025 · fourth_quarter · Q4
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROYAL BIOLOGICS via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · third_quarter · Q3
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (S. 2561). Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (S. 2561). Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2025 · third_quarter · Q3
Education on Human Cellular Tissue Products (HCTPs).
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2025 · third_quarter · Q3
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2025 · third_quarter · Q3
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act Issues related to physician reimbursement under the Medicare physician fee schedule.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act, including the No Surprises Act Enforcement Act (H.R. 4710/S. 2420).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2025 · third_quarter · Q3
Advocating for access to and reimbursement for biosimilars.
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2025 · third_quarter · Q3
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to site neutrality. Issues related to provider and insurer payment transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2025 · third_quarter · Q3
Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P). Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2025 · third_quarter · Q3
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments, including the Infertility Treatment Affordability Act (H.R. 4639).
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2025 · second_quarter · Q2
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to IVF treatments.
Support for S. 839, EPIC Act and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Policies related to the Most Favored Nation Drug Pricing Model
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2025 · second_quarter · Q2
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to restructuring at the Department of Health and Human Services. Issues related to the implementation of the Medical Device User Fee Act (MDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to physician payment under the Medicare physician fee schedule. Issues related to telehealth services, H.R. 1614- To amend title XVIII of the Social Security Act to expand practitioners eligible to furnish telehealth services under the Medicare program. H.R. 2013- Medicare Home Health Accessibility Act. Issues related to the supervision requirements for physician and occupational therapy assistants for covered outpatient services under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2025 · second_quarter · Q2
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.842/S. 339- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2025 · second_quarter · Q2
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Advocating for access to and reimbursement for biosimilars. Issues related to patient access to infusion products for asthma and allergies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Issues related to access and physician reimbursement under Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 879 - Medicare Patient Access and Practice Stabilization Act. Issues related to physician reimbursement for Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2025 · second_quarter · Q2
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including H.R. 3134, the Emergency Care Improvement Act Issues related to physician reimbursement under the Medicare physician fee schedule.
Issues relating to the implementation of provisions included in Subtitle BB of PL.116-260- No Surprises Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2025 · second_quarter · Q2
Education on Human Cellular Tissue Products (HCTPs).
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · second_quarter · Q2
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2025 · second_quarter · Q2
Advocacy for increased patient access and reimbursement to ambulatory surgical centers. Issues related to Medicare beneficiary and commercially insured patients to ASCs. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Issues related to site neutrality. Issues related to provider and insurer payment transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIVEX BIOLOGICS via THE MCMANUS GROUP
2025 · first_quarter · Q1
Education on Human Cellular Tissue Products (HCTPs).
Issues related to coverage of Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2025 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers.
Issues related to Artificial Intelligences approval in Medical Devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOWOUND SOLUTIONS via THE MCMANUS GROUP
2025 · first_quarter · Q1
Issues related to coverage of Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ACESSO BIOLOGICS via THE MCMANUS GROUP
2025 · first_quarter · Q1
Issues related to coverage of Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE